Cardiorenal syndrome

被引：4

作者：

Ketteler M. ^{[1
]}

Biggar P.H. ^{[1
]}

机构：

[1] Medizinische Klinik III, Nephrologie, Klinikum Coburg, Coburg 96450

来源：

Der Nephrologe | 2010年 / 5卷 / 1期

关键词：

Acute kidney injury; Cardiovascular mortality; Chronic kidney disease; Risk factors;

D O I：

10.1007/s11560-009-0338-0

中图分类号：

学科分类号：

摘要：

Only in the last decade has it been recognized that chronic kidney disease (CKD) and chronic renal failure represent potent cardiovascular risk predictors. With glomerular filtration rates below 60 ml/min, the risk of cardiovascular events rises steeply, but an increased prevalence of traditional risk factors cannot be held responsible for this observation. Therefore, a pathological and specific cardiorenal communication seems to be associated with progressive renal function loss. However, there is not just "crosstalk" from CKD to cardiovascular morbidity, but heart and kidney also interact with each other in any situation involving acute injury of each organ. This perception prompted a working group, with Ronco coining the term "cardiorenal syndrome" and developing a classification of this term into five categories. Although this classification still lacks full international and evidence-based approval, the possibility appears that it may develop into a clinically useful concept, which is outlined in this review. © 2010 Springer-Verlag.

引用

页码：49 / 57

页数：8

共 28 条

[1]

USRDS 2005 Annual Report, (2005)

[2]

Ruilope, J Am Soc Nephrol, 12, (2001)

[3]

Mann, Ann Intern Med, 134, (2001)

[4]

Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.-Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, New England Journal of Medicine, 351, 13, (2004)

[5]

Anavekar N.S., McMurray J.J.V., Velazquez E.J., Solomon S.D., Kober L., Rouleau J.-L., White H.D., Nordlander R., Maggioni A., Dickstein K., Zelenkofske S., Leimberger J.D., Califf R.M., Pfeffer M.A., Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction, New England Journal of Medicine, 351, 13, pp. 1285-1295, (2004)

[6]

Go A.S., Lo J.C., Epidemiology of non-dialysis-requiring chronic kidney disease and cardiovascular disease, Current Opinion in Nephrology and Hypertension, 15, 3, pp. 296-302, (2006)

[7]

Drueke T.B., Locatelli F., Clyne N., Eckardt K.-U., Macdougall I.C., Tsakiris D., Burger H.-U., Scherhag A., Normalization of hemoglobin level in patients with chronic kidney disease and anemia, New England Journal of Medicine, 355, 20, pp. 2071-2084, (2006)

[8]

Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., Reddan D., Correction of anemia with epoetin alfa in chronic kidney disease, New England Journal of Medicine, 355, 20, pp. 2085-2098, (2006)

[9]

Pfeffer, N Engl J Med, 361, (2009)

[10]

Wrone E.M., Hornberger J.M., Zehnder J.L., McCann L.M., Coplon N.S., Fortmann S.P., Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease, Journal of the American Society of Nephrology, 15, 2, pp. 420-426, (2004)

← 1 2 3 →